Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison,JACC: Heart Failure

当前位置： X-MOL 学术 › JACC Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison
JACC: Heart Failure ( IF 10.3 ) Pub Date : 2024-03-13 , DOI: 10.1016/j.jchf.2024.02.020
John W Ostrominski ₁ , Ersilia M DeFilippis ₂ , Kannu Bansal ₃ , Ralph J Riello ₄ , Biykem Bozkurt ₅ , Paul A Heidenreich ₆ , Muthiah Vaduganathan ₇

Affiliation

This review serves to compare contemporary clinical practice recommendations for the management of heart failure (HF), as codified in the 2021 European Society of Cardiology (ESC) guideline, the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) guideline, and the 2023 focused update of the 2021 ESC document. Overall, these guidelines aim to solidify significant advances throughout the HF continuum since the publication of previous full guideline iterations (2013 and 2016 for the ACC/AHA and ESC, respectively). All guidelines provide new recommendations for an increasingly complex landscape of HF care, with focus on primary HF prevention, HF stages, rapid initiation and optimization of evidence-based pharmacotherapies, overlapping cardiac and noncardiac comorbidities, device-based therapies, and management pathways for special groups of patients, including those with cardiac amyloidosis. Importantly, the ACC/AHA/HFSA document features special emphasis on HF risk prediction and screening, cost/value, social determinants of health, and health care disparities. The review discusses major similarities and differences between these recent guidelines and guideline updates, as well as their potential downstream implications for clinical care.

中文翻译：

当代美国和欧洲心力衰竭管理指南：JACC：心力衰竭指南比较

本综述旨在比较当代心力衰竭 (HF) 管理的临床实践建议，如 2021 年欧洲心脏病学会 (ESC) 指南、2022 年美国心脏病学会 (ACC)/美国心脏协会 (AHA)/美国心力衰竭协会 (HFSA) 指南，以及 2021 年 ESC 文件的 2023 年重点更新。总体而言，这些指南旨在巩固自先前完整指南迭代（ACC/AHA 和 ESC 分别为 2013 年和 2016 年）发布以来整个 HF 连续体的重大进展。所有指南都为日益复杂的心力衰竭护理提供了新的建议，重点关注心力衰竭的初级预防、心力衰竭分期、循证药物治疗的快速启动和优化、心脏和非心脏合并症的重叠、基于设备的治疗以及特殊情况的管理途径。患者群体，包括患有心脏淀粉样变性的患者。重要的是，ACC/AHA/HFSA 文件特别强调心力衰竭风险预测和筛查、成本/价值、健康的社会决定因素以及医疗保健差异。该综述讨论了这些最新指南和指南更新之间的主要异同，以及它们对临床护理的潜在下游影响。

更新日期：2024-03-13

点击分享查看原文

点击收藏

阅读更多本刊新发论文